SG11201908919XA - Combination therapies targeting pd-1, tim-3, and lag-3 - Google Patents
Combination therapies targeting pd-1, tim-3, and lag-3Info
- Publication number
- SG11201908919XA SG11201908919XA SG11201908919XA SG11201908919XA SG 11201908919X A SG11201908919X A SG 11201908919XA SG 11201908919X A SG11201908919X A SG 11201908919XA SG 11201908919X A SG11201908919X A SG 11201908919XA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- rule
- tim
- lag
- applicant
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Endocrinology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Ultra Sonic Daignosis Equipment (AREA)
- Memory System Of A Hierarchy Structure (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201762481973P | 2017-04-05 | 2017-04-05 | |
PCT/EP2018/058752 WO2018185232A1 (en) | 2017-04-05 | 2018-04-05 | Combination therapies targeting pd-1, tim-3, and lag-3 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201908919XA true SG11201908919XA (en) | 2019-10-30 |
Family
ID=62027945
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912941PA SG10201912941PA (en) | 2017-04-05 | 2018-04-05 | Combination therapies targeting pd-1, tim-3, and lag-3 |
SG11201908919X SG11201908919XA (en) | 2017-04-05 | 2018-04-05 | Combination therapies targeting pd-1, tim-3, and lag-3 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912941PA SG10201912941PA (en) | 2017-04-05 | 2018-04-05 | Combination therapies targeting pd-1, tim-3, and lag-3 |
Country Status (19)
Country | Link |
---|---|
US (3) | US11939380B2 (zh) |
EP (3) | EP4230654A1 (zh) |
JP (3) | JP2020513009A (zh) |
KR (2) | KR20220083863A (zh) |
CN (2) | CN114984209A (zh) |
AU (2) | AU2018247916A1 (zh) |
BR (1) | BR112019020662A2 (zh) |
CA (2) | CA3185303A1 (zh) |
CL (2) | CL2019002850A1 (zh) |
CO (1) | CO2019012080A2 (zh) |
EA (1) | EA201992350A1 (zh) |
IL (1) | IL269644A (zh) |
MA (1) | MA49042A (zh) |
MX (2) | MX2019011961A (zh) |
PE (1) | PE20191741A1 (zh) |
PH (1) | PH12019502191A1 (zh) |
SG (2) | SG10201912941PA (zh) |
TW (2) | TWI822101B (zh) |
WO (1) | WO2018185232A1 (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
HUE056677T2 (hu) | 2016-04-12 | 2022-02-28 | Symphogen As | Anti-tim-3 ellenanyagok és készítmények |
TWI780057B (zh) | 2016-07-14 | 2022-10-11 | 美商必治妥美雅史谷比公司 | 針對tim3之抗體及其用途 |
CN117586403A (zh) | 2016-10-11 | 2024-02-23 | 艾吉纳斯公司 | 抗lag-3抗体及其使用方法 |
MA46525A (fr) | 2016-10-13 | 2019-08-21 | Symphogen As | Anticorps anti-lag-3 et compositions |
MA49033B1 (fr) | 2017-04-03 | 2022-10-31 | Hoffmann La Roche | Immunoconjugué d'un anticorps contre pd-1 avec il-2 mutée ou avec il-15 |
UA128451C2 (uk) | 2017-04-05 | 2024-07-17 | Ф. Хоффманн-Ля Рош Аг | Біспецифічне антитіло, яке специфічно зв'язується з pd1 і lag3 |
KR20220083863A (ko) | 2017-04-05 | 2022-06-20 | 심포젠 에이/에스 | Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법 |
US10894833B2 (en) * | 2017-07-20 | 2021-01-19 | H. Lundbeck A/S | Agents, uses and methods for treatment |
CN111253485A (zh) * | 2018-11-30 | 2020-06-09 | 上海开拓者生物医药有限公司 | 抗人tim-3单克隆抗体及其应用 |
KR20220007593A (ko) * | 2019-05-13 | 2022-01-18 | 리제너론 파마슈티칼스 인코포레이티드 | 암 치료에서의 효능 강화를 위한 pd-1 억제제와 lag-3 억제제의 병용 |
CN113214396B (zh) * | 2020-07-31 | 2022-04-19 | 北京市神经外科研究所 | 抗tim3的单链抗体及其在制备治疗肿瘤的药物中的用途 |
CN112812179B (zh) * | 2021-01-19 | 2022-07-22 | 北京大学 | 高亲和力高特异性抗cmtm6单克隆抗体及其用途 |
WO2023240082A2 (en) * | 2022-06-07 | 2023-12-14 | Incyte Corporation | Combination therapy of anti-pd-1 active agent, anti-tim-3 active agent, and anti-lag-3 active agent for treating cancer |
WO2024041652A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment |
WO2024041651A1 (en) * | 2022-08-25 | 2024-02-29 | Beigene, Ltd. | Methods of cancer treatment using anti-pd1 antibodies in combination with anti-tim3 antibodies and anti-lag3 antibodies |
WO2024051670A1 (zh) * | 2022-09-06 | 2024-03-14 | 正大天晴药业集团股份有限公司 | 结合tim-3的抗体与结合pd-1的抗体的药物组合 |
Family Cites Families (77)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4399216A (en) | 1980-02-25 | 1983-08-16 | The Trustees Of Columbia University | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US5179017A (en) | 1980-02-25 | 1993-01-12 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4634665A (en) | 1980-02-25 | 1987-01-06 | The Trustees Of Columbia University In The City Of New York | Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials |
US4510245A (en) | 1982-11-18 | 1985-04-09 | Chiron Corporation | Adenovirus promoter system |
US4740461A (en) | 1983-12-27 | 1988-04-26 | Genetics Institute, Inc. | Vectors and methods for transformation of eucaryotic cells |
US5168062A (en) | 1985-01-30 | 1992-12-01 | University Of Iowa Research Foundation | Transfer vectors and microorganisms containing human cytomegalovirus immediate-early promoter-regulatory DNA sequence |
DE3668186D1 (de) | 1985-04-01 | 1990-02-15 | Celltech Ltd | Transformierte myeloma-zell-linie und dieselbe verwendendes verfahren zur expression eines gens, das ein eukaryontisches polypeptid kodiert. |
US4968615A (en) | 1985-12-18 | 1990-11-06 | Ciba-Geigy Corporation | Deoxyribonucleic acid segment from a virus |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US4959455A (en) | 1986-07-14 | 1990-09-25 | Genetics Institute, Inc. | Primate hematopoietic growth factors IL-3 and pharmaceutical compositions |
US4912040A (en) | 1986-11-14 | 1990-03-27 | Genetics Institute, Inc. | Eucaryotic expression system |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
MX9605365A (es) | 1994-05-06 | 1997-12-31 | Roussy Inst Gustave | Fracciones polipeptidicas solubles de la proteina lag-3; procedimiento de produccion; composicion terapeutica y anticuerpos ant-idiotipo. |
US6517529B1 (en) | 1999-11-24 | 2003-02-11 | Radius International Limited Partnership | Hemodialysis catheter |
IL151853A0 (en) | 2000-04-11 | 2003-04-10 | Genentech Inc | Multivalent antibodies and uses therefor |
EA013225B1 (ru) | 2003-01-07 | 2010-04-30 | Симфоген А/С | Способ получения линии клеток, продуцирующей рекомбинантный поликлональный белок, способ получения поликлонального белка, линия клеток, продуцирующая рекомбинантный поликлональный белок, библиотека векторов, популяция клеток |
TWI309240B (en) | 2004-09-17 | 2009-05-01 | Hoffmann La Roche | Anti-ox40l antibodies |
EP2439272A3 (en) | 2005-05-09 | 2013-07-31 | Ono Pharmaceutical Co., Ltd. | Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics |
US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
AU2007286451A1 (en) | 2006-08-17 | 2008-02-21 | F. Hoffmann-La Roche Ag | A conjugate of an antibody against CCR5 and an antifusogenic peptide |
EP1987839A1 (en) | 2007-04-30 | 2008-11-05 | I.N.S.E.R.M. Institut National de la Sante et de la Recherche Medicale | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
US9244059B2 (en) | 2007-04-30 | 2016-01-26 | Immutep Parc Club Orsay | Cytotoxic anti-LAG-3 monoclonal antibody and its use in the treatment or prevention of organ transplant rejection and autoimmune disease |
NZ581316A (en) | 2007-05-25 | 2012-02-24 | Symphogen As | Method for manufacturing a recombinant polyclonal protein |
PL2170959T3 (pl) | 2007-06-18 | 2014-03-31 | Merck Sharp & Dohme | Przeciwciała przeciwko ludzkiemu receptorowi programowanej śmierci PD-1 |
EP2252319A2 (en) | 2008-01-29 | 2010-11-24 | The Brigham and Women's Hospital, Inc. | Methods for modulating a population of myeloid-derived suppressor cells and uses thereof |
EP2280998A1 (en) | 2008-04-23 | 2011-02-09 | Symphogen A/S | Methods for manufacturing a polyclonal protein |
AR072999A1 (es) | 2008-08-11 | 2010-10-06 | Medarex Inc | Anticuerpos humanos que se unen al gen 3 de activacion linfocitaria (lag-3) y los usos de estos |
EP2342228B1 (en) | 2008-09-12 | 2017-09-06 | Oxford University Innovation Limited | Pd-1 specific antibodies and uses thereof |
EP2342229A1 (en) | 2008-09-12 | 2011-07-13 | ISIS Innovation Limited | Pd-1 specific antibodies and uses thereof |
KR20110081284A (ko) | 2008-10-06 | 2011-07-13 | 심포젠 에이/에스 | 조합 약물 제품에 대한 약물 후보물질의 동정방법 및 선택방법 |
JP5569946B2 (ja) | 2009-01-26 | 2014-08-13 | 国立大学法人 岡山大学 | 免疫抑制剤および自己免疫疾患の予防および治療剤 |
US8647623B2 (en) | 2009-04-10 | 2014-02-11 | Kyowa Hakko Kirin Co., Ltd | Method for treatment of blood tumor using anti-TIM-3 antibody |
TW201134488A (en) | 2010-03-11 | 2011-10-16 | Ucb Pharma Sa | PD-1 antibodies |
EP2581113B1 (en) | 2010-06-11 | 2018-05-09 | Kyowa Hakko Kirin Co., Ltd. | Anti-tim-3 antibody |
CA2802344C (en) * | 2010-06-18 | 2023-06-13 | The Brigham And Women's Hospital, Inc. | Bi-specific antibodies against tim-3 and pd-1 for immunotherapy in chronic immune conditions |
US9217039B2 (en) | 2010-11-01 | 2015-12-22 | Symphogen A/S | Anti-HER3 antibodies and compositions |
LT2691112T (lt) | 2011-03-31 | 2018-07-25 | Merck Sharp & Dohme Corp. | Stabilios antikūnų kompozicijos prieš žmogaus programuojamos mirties receptorių pd-1 ir susiję gydymo būdai |
US8841418B2 (en) | 2011-07-01 | 2014-09-23 | Cellerant Therapeutics, Inc. | Antibodies that specifically bind to TIM3 |
KR101933990B1 (ko) | 2012-05-02 | 2018-12-31 | 심포젠 에이/에스 | 인간화 panher 항체 조성물 |
UY34887A (es) | 2012-07-02 | 2013-12-31 | Bristol Myers Squibb Company Una Corporacion Del Estado De Delaware | Optimización de anticuerpos que se fijan al gen de activación de linfocitos 3 (lag-3) y sus usos |
SG11201505960VA (en) | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
HUE049957T2 (hu) | 2013-03-15 | 2020-11-30 | Glaxosmithkline Ip Dev Ltd | Lag-3 elleni kötõfehérjék |
CN104250302B (zh) | 2013-06-26 | 2017-11-14 | 上海君实生物医药科技股份有限公司 | 抗pd‑1抗体及其应用 |
WO2015035606A1 (en) | 2013-09-13 | 2015-03-19 | Beigene, Ltd. | Anti-pd1 antibodies and their use as therapeutics and diagnostics |
HUE062317T2 (hu) * | 2013-09-20 | 2023-10-28 | Bristol Myers Squibb Co | Anti-LAG-3 antitestek és anti-PD-1 antitestek kombinációja tumorok kezeléséhez |
US10570204B2 (en) | 2013-09-26 | 2020-02-25 | The Medical College Of Wisconsin, Inc. | Methods for treating hematologic cancers |
PL3081576T3 (pl) | 2013-12-12 | 2020-03-31 | Shanghai Hengrui Pharmaceutical Co., Ltd. | Przeciwciało anty pd-1, jego fragment wiążący antygen i ich zastosowanie medyczne |
TWI681969B (zh) | 2014-01-23 | 2020-01-11 | 美商再生元醫藥公司 | 針對pd-1的人類抗體 |
JOP20200094A1 (ar) | 2014-01-24 | 2017-06-16 | Dana Farber Cancer Inst Inc | جزيئات جسم مضاد لـ pd-1 واستخداماتها |
CN103936853B (zh) | 2014-01-26 | 2016-08-17 | 中国人民解放军军事医学科学院基础医学研究所 | 一种检测tim-3试剂盒及其使用方法 |
JOP20200096A1 (ar) | 2014-01-31 | 2017-06-16 | Children’S Medical Center Corp | جزيئات جسم مضاد لـ tim-3 واستخداماتها |
AU2015228372B2 (en) | 2014-03-12 | 2018-05-31 | Yeda Research And Development Co. Ltd | Reducing systemic regulatory T cell levels or activity for treatment of disease and injury of the CNS |
EP3116909B1 (en) | 2014-03-14 | 2019-11-13 | Novartis Ag | Antibody molecules to lag-3 and uses thereof |
IL248511B (en) * | 2014-05-13 | 2022-07-01 | Bavarian Nordic As | Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3 |
SG10201900571YA (en) | 2014-07-22 | 2019-02-27 | Cb Therapeutics Inc | Anti-pd-1 antibodies |
JO3663B1 (ar) | 2014-08-19 | 2020-08-27 | Merck Sharp & Dohme | الأجسام المضادة لمضاد lag3 وأجزاء ربط الأنتيجين |
TWI595006B (zh) | 2014-12-09 | 2017-08-11 | 禮納特神經系統科學公司 | 抗pd-1抗體類和使用彼等之方法 |
EP3916017A1 (en) | 2014-12-22 | 2021-12-01 | PD-1 Acquisition Group, LLC | Anti-pd-1 antibodies |
WO2016111947A2 (en) | 2015-01-05 | 2016-07-14 | Jounce Therapeutics, Inc. | Antibodies that inhibit tim-3:lilrb2 interactions and uses thereof |
MA41463A (fr) * | 2015-02-03 | 2017-12-12 | Anaptysbio Inc | Anticorps dirigés contre le gène d'activation 3 des lymphocytes (lag-3) |
US9873741B2 (en) | 2015-03-06 | 2018-01-23 | Sorrento Therapeutics, Inc. | Antibody therapeutics that bind TIM3 |
TWI773646B (zh) | 2015-06-08 | 2022-08-11 | 美商宏觀基因股份有限公司 | 結合lag-3的分子和其使用方法 |
US20180207273A1 (en) | 2015-07-29 | 2018-07-26 | Novartis Ag | Combination therapies comprising antibody molecules to tim-3 |
WO2017031242A1 (en) | 2015-08-20 | 2017-02-23 | Sutro Biopharma, Inc. | Anti-tim-3 antibodies, compositions comprising anti-tim-3 antibodies and methods of making and using anti-tim-3 antibodies |
US12030942B2 (en) | 2015-10-02 | 2024-07-09 | Les Laboratoires Servier | Anti-PD-1 antibodies and compositions |
US10287352B2 (en) | 2015-10-02 | 2019-05-14 | Hoffman-La Roche Inc. | Bispecific antibodies specific for PD1 and TIM3 |
KR20180053752A (ko) * | 2015-10-02 | 2018-05-23 | 심포젠 에이/에스 | 항-pd-1 항체 및 조성물 |
HUE056677T2 (hu) | 2016-04-12 | 2022-02-28 | Symphogen As | Anti-tim-3 ellenanyagok és készítmények |
AR108516A1 (es) | 2016-05-18 | 2018-08-29 | Boehringer Ingelheim Int | Moléculas de anticuerpo anti-pd1 y anti-lag3 para el tratamiento del cáncer |
TWI780057B (zh) | 2016-07-14 | 2022-10-11 | 美商必治妥美雅史谷比公司 | 針對tim3之抗體及其用途 |
JOP20190013A1 (ar) | 2016-08-25 | 2019-01-31 | Lilly Co Eli | أجسام مضادة لـ (تي آي ام -3) |
MA46525A (fr) | 2016-10-13 | 2019-08-21 | Symphogen As | Anticorps anti-lag-3 et compositions |
EA201991214A1 (ru) | 2016-11-18 | 2019-10-31 | Антитела против pd-1 и их композиции | |
JOP20190133A1 (ar) | 2016-12-08 | 2019-06-02 | Innovent Biologics Suzhou Co Ltd | أجسام مضادة لـ Tim-3 لمزجها بأجسام مضادة لـ PD-1 |
KR20220083863A (ko) * | 2017-04-05 | 2022-06-20 | 심포젠 에이/에스 | Pd-1, tim-3 및 lag-3을 표적화하는 조합 요법 |
JOP20190222A1 (ar) | 2017-04-11 | 2019-09-24 | Zymeworks Inc | الأجسام المضادة ثنائية النوعية المضادة لـ pd-l1 والمضادة لـ tim-3 |
-
2018
- 2018-04-05 KR KR1020227019731A patent/KR20220083863A/ko not_active Application Discontinuation
- 2018-04-05 JP JP2019554785A patent/JP2020513009A/ja active Pending
- 2018-04-05 SG SG10201912941PA patent/SG10201912941PA/en unknown
- 2018-04-05 CN CN202210655817.7A patent/CN114984209A/zh active Pending
- 2018-04-05 AU AU2018247916A patent/AU2018247916A1/en active Pending
- 2018-04-05 CA CA3185303A patent/CA3185303A1/en active Pending
- 2018-04-05 CA CA3058960A patent/CA3058960C/en active Active
- 2018-04-05 EA EA201992350A patent/EA201992350A1/ru unknown
- 2018-04-05 MX MX2019011961A patent/MX2019011961A/es unknown
- 2018-04-05 EP EP23161859.6A patent/EP4230654A1/en active Pending
- 2018-04-05 WO PCT/EP2018/058752 patent/WO2018185232A1/en active Application Filing
- 2018-04-05 BR BR112019020662A patent/BR112019020662A2/pt unknown
- 2018-04-05 US US16/500,918 patent/US11939380B2/en active Active
- 2018-04-05 MA MA049042A patent/MA49042A/fr unknown
- 2018-04-05 EP EP18719068.1A patent/EP3606957A1/en active Pending
- 2018-04-05 KR KR1020197030876A patent/KR20190137105A/ko not_active Application Discontinuation
- 2018-04-05 SG SG11201908919X patent/SG11201908919XA/en unknown
- 2018-04-05 PE PE2019001998A patent/PE20191741A1/es unknown
- 2018-04-05 EP EP22177869.9A patent/EP4116328A1/en active Pending
- 2018-04-05 CN CN201880032633.7A patent/CN110621698B/zh active Active
- 2018-04-09 TW TW111121455A patent/TWI822101B/zh active
- 2018-04-09 TW TW107112114A patent/TWI801376B/zh active
-
2019
- 2019-09-24 PH PH12019502191A patent/PH12019502191A1/en unknown
- 2019-09-25 IL IL26964419A patent/IL269644A/en unknown
- 2019-10-04 CL CL2019002850A patent/CL2019002850A1/es unknown
- 2019-10-04 MX MX2022007140A patent/MX2022007140A/es unknown
- 2019-10-29 CO CONC2019/0012080A patent/CO2019012080A2/es unknown
-
2021
- 2021-12-01 CL CL2021003196A patent/CL2021003196A1/es unknown
-
2022
- 2022-06-07 US US17/834,554 patent/US20220380470A1/en active Pending
- 2022-06-09 JP JP2022093937A patent/JP7523491B2/ja active Active
- 2022-06-10 AU AU2022204078A patent/AU2022204078A1/en active Pending
-
2023
- 2023-11-02 JP JP2023188380A patent/JP2024023222A/ja active Pending
-
2024
- 2024-02-16 US US18/444,187 patent/US20240270848A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
SG11201908919XA (en) | Combination therapies targeting pd-1, tim-3, and lag-3 | |
SG11201907451XA (en) | Substituted imidazo-quinolines as nlrp3 modulators | |
SG11201809082WA (en) | Nlrp3 modulators | |
SG11201811432WA (en) | Rna for cancer therapy | |
SG11201808622SA (en) | Chimeric receptors to flt3 and methods of use thereof | |
SG11201903830TA (en) | Blockade of cd7 expression and chimeric antigen receptors for immunotherapy of t-cell malignancies | |
SG11201811184UA (en) | Lag -3 binding members | |
SG11201810600WA (en) | Fxr (nr1h4) modulating compounds | |
SG11201811564QA (en) | Methods of treating ovarian cancer | |
SG11201907867TA (en) | Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine | |
SG11201811431VA (en) | Multispecific antibodies against cd40 and cd137 | |
SG11201804510PA (en) | Biparatopic polypeptides antagonizing wnt signaling in tumor cells | |
SG11201907604UA (en) | Crystalline forms of the 4-pyrimidinesulfamide derivative aprocitentan | |
SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
SG11201804673WA (en) | Novel anti-claudin antibodies and methods of use | |
SG11201903737PA (en) | Neutralizing anti-tl1a monoclonal antibodies | |
SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
SG11201809374VA (en) | Cd40l-fc fusion polypeptides and methods of use thereof | |
SG11201907927SA (en) | Binding molecules that specifically bind to tau | |
SG11201900238UA (en) | Compounds and methods for modulation of smn2 | |
SG11201903061YA (en) | Combination treatments comprising administration of imidazopyrazinones | |
SG11201807523PA (en) | Ilt7 binding molecules and methods of using the same | |
SG11201906557UA (en) | Novel stable formulation for fxia antibodies | |
SG11201903312VA (en) | Sulfoxyalkyl organonitro and related compounds and pharmaceutical compositions for use in medicine |